EUVIMEDOpdag EUVIMED
Randomisierte kontrollierte StudieKlinische Studie (Phase I)Open access · CC BY-NC-ND 4.0

A Randomized, Double‐Blind, Placebo‐Controlled Phase 1 Study of Adiponectin Agonist ( PEG )‐ BHD1028 in People With Insulin Resistance

Pablo Lapuerta iD, Brian B Kim iD

Clinical and Translational Science · 2026

DOI: 10.1111/cts.70596 ↗

At a glance

Randomisierte kontrollierte Studie in Clinical and Translational Science, 2026. Written by Pablo Lapuerta and 1 co-authors. Institution: Lapuerta Consulting LLC, Skillman, New Jersey, USA. Major MEDLINE topics: Insulin Resistance, Adiponectin, Receptors, Adiponectin. Cited 1 times so far (Crossref); 20 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Encuragen.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Low adiponectin levels may contribute to insulin resistance. This first‐in‐human study evaluated adiponectin receptor agonist (PEG)‐BHD1028 in subjects with insulin resistance. Adults with BMI ≥ 27 kg/m 2 , HOMA‐IR ≥ 1.8, and HbA1c < 6.5% received subcutaneous injections of (PEG)‐BHD1028 or placebo in single‐ascending dose (SAD) cohorts (4, 8, 16, 32, and 64 μg/kg) and multiple‐ascending dose (MAD) cohorts for 28 days (8, 16, and 32 μg/kg QD). Each cohort had eight subjects, with two on placebo. Area under the curve (AUC) was obtained for insulin c‐peptide, insulin, and glucose in a mixed meal tolerance test (MMTT) at Day −1 and Day 28. Body weight, triglycerides, and inflammatory markers were measured at regular intervals. Changes were analyzed by the Kruskal–Wallis test (for MMTT) and generalized estimating equations (GEEs). The MAD cohort mean age was 49 years, with a body mass index of 32, baseline HOMA‐IR 3.8, and 42% female. Mild gastrointestinal adverse events occurred on (PEG)‐BHD1028 (50%) and placebo (33%) without discontinuations. Drug exposure was proportional to dose. Insulin c‐peptide AUC changes were +25% on placebo and −63%, + 24%, and + 2% on (PEG)‐BHD1028 8, 16, and 32 μg/kg doses ( p < 0.001). Reductions in insulin ( p = 0.116) were also observed, with the greatest percentage change on 8 μg/kg. There were no consistent differences between groups in body weight, triglycerides, and inflammatory markers. Adiponectin agonist (PEG)‐BHD1028 was well‐tolerated with dose‐related increases in exposure. Observed effects on insulin c‐peptide and insulin during the MMTT support further development.

Subjects

MeSH terms (MEDLINE)

Insulin ResistanceAdiponectinReceptors, AdiponectinHumansFemaleMaleMiddle AgedDouble-Blind MethodAdultBlood GlucoseC-PeptideInsulinBody Mass IndexArea Under CurveDose-Response Relationship, Drug

Author keywords

BHD1028adiponectininsulin resistanceobesitypost‐prandial glucose

Substances

AdiponectinBlood GlucoseC-PeptideInsulinADIPOQ protein, humanReceptors, Adiponectin

Authors and institutions

  • Lapuerta Consulting LLC, Skillman, New Jersey, USA.
  • EncuraGen Inc., Anyang, Republic of Korea.

ORCID profiles: Pablo Lapuerta, Brian B Kim

Funding

  • Encuragen

Cite

APA

Lapuerta, P., & Kim, B. B. (2026). A Randomized, Double‐Blind, Placebo‐Controlled Phase 1 Study of Adiponectin Agonist ( PEG )‐ BHD1028 in People With Insulin Resistance. Clinical and Translational Science. https://doi.org/10.1111/cts.70596

Vancouver

Lapuerta P, Kim BB. A Randomized, Double‐Blind, Placebo‐Controlled Phase 1 Study of Adiponectin Agonist ( PEG )‐ BHD1028 in People With Insulin Resistance. Clinical and Translational Science. 2026. doi:10.1111/cts.70596

BibTeX
@article{Lapuerta2026,
  author = {Lapuerta, Pablo and Kim, Brian B},
  title = {A Randomized, Double‐Blind, Placebo‐Controlled Phase 1 Study of Adiponectin Agonist ( PEG )‐ BHD1028 in People With Insulin Resistance},
  journal = {Clinical and Translational Science},
  year = {2026},
  doi = {10.1111/cts.70596}
}
Start for free →